Drug
Valdecoxib clinical trials
- studies test it
- 23
- open now
- 0
- in phase 3
- 10
- first study started
- 2001
How studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
23 studies that test it; most in 2003 (8)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 7 |
| 2003 | 8 |
| 2004 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 2
- Phase 3
- 10
- Phase 4
- 10
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 6
Pfizer (16) · Penn State University (1) · Merck Sharp & Dohme LLC (1) · Dana-Farber Cancer Institute (1) · Helsinki University Central Hospital (1) · Asker & Baerum Hospital (1) · University of Washington (1) · All India Institute of Medical Sciences, New Delhi (1)
Often tested with
Tested in the same studies.
Diclofenac (4) · Parecoxib (4) · Naproxen (3) · Piroxicam (1) · Etoricoxib (1) · Dexamethasone (1) · Rofecoxib (1) · Nitroglycerin (1)
Studies
Open first, then newest update. How each study uses valdecoxib is read from its arms, and is right about nine times in ten.
Testing it · 23
- A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)CompletedPhase 2PfizerNCT00650624Written as valdecoxib
- A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In TaiwanCompletedPhase 3PfizerNCT00648258Written as valdecoxib
- A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary DysmenorrheaCompletedPhase 4PfizerNCT00649415Written as valdecoxib
- Analgesic Efficacy Of Valdecoxib In Patients Following Bunion SurgeryCompletedPhase 3PfizerNCT00653354Written as valdecoxib
- A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle SprainTerminatedPhase 4PfizerNCT00657449Written as valdecoxib
- Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia in Healthy VolunteersCompletedPhase 4Penn State UniversityNCT00260325Written as valdecoxib
- A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00092300Written as Comparator: valdecoxib
- Valdecoxib in Treating Chronic Pain in Cancer PatientsCompletedNot applicableDana-Farber Cancer InstituteNCT00021996Written as valdecoxib
- NSAIDs With Morphine-PCA Compared to Epidural Analgesia in Thoracotomy PainCompletedNot applicableHelsinki University Central HospitalNCT01541137Written as parecoxib/ valdecoxib
- COX-2 Inhibitor Versus Glucocorticoid Versus Both CombinedCompletedPhase 4Asker & Baerum HospitalNCT01361789Written as parecoxib, valdecoxib, etoricoxib
- A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal SurgeryTerminatedPhase 3PfizerNCT00651300Written as Parecoxib/Valdecoxib
- Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)TerminatedPhase 2/3All India Institute of Medical Sciences, New DelhiNCT00419549Written as Valdecoxib
- A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy for Anterior Cruciate Ligament (ACL) ReconstructionCompletedPhase 4PfizerNCT00650598Written as valdecoxib
- Perioperative Inflammation and Cyclooxygenase 2 (COX-2)CompletedPhase 4University of WashingtonNCT00122096Written as valdecoxib
- Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis PatientsCompletedPhase 4PfizerNCT00650455Written as valdecoxib
- Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) ReconstructionCompletedPhase 3PfizerNCT00650039Written as valdecoxib
- Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy SurgeryCompletedPhase 3PfizerNCT00683137Written as valdecoxib
- A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained AnkleCompletedPhase 4PfizerNCT00671320Written as valdecoxib
- A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore ThroatCompletedPhase 3PfizerNCT00647829Written as valdecoxib
- A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery PainCompletedPhase 3PfizerNCT00661635Written as valdecoxib
Codes
What other systems call valdecoxib · ClinicalTrials.gg INT004223
- MeSH (NLM) C406224valdecoxibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2919279Q3WVALDECOXIBConfirmed FDA, NLM, Wikidata
- RxNorm 278567Confirmed FDA, Wikidata
- Wikidata Q347613valdecoxibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1869ValdecoxibOne source FDA
- DrugBank DB00580One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C406224 | valdecoxib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2919279Q3W | VALDECOXIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 278567 | — | Confirmed FDA, Wikidata |
| Wikidata | Q347613 | valdecoxib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1869 | Valdecoxib | One source FDA |
| DrugBank | DB00580 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.